Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes
- 1 March 2001
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 87 (5) , 532-536
- https://doi.org/10.1016/s0002-9149(00)01426-0
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control groupStatistics in Medicine, 1998
- Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1998
- A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable AnginaNew England Journal of Medicine, 1998
- Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial InfarctionNew England Journal of Medicine, 1998
- Estimating Causal Effects from Large Data Sets Using Propensity ScoresAnnals of Internal Medicine, 1997
- Design and Methodology of the PURSUIT TrialThe American Journal of Cardiology, 1997
- Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyThe Lancet, 1997
- Reactivation of Unstable Angina after the Discontinuation of HeparinNew England Journal of Medicine, 1992
- Performance of tests of significance based on stratification by a multivariate confounder score or by a propensity scoreJournal of Clinical Epidemiology, 1989
- Aspirin, Heparin, or Both to Treat Acute Unstable AnginaNew England Journal of Medicine, 1988